Cullinan Therapeutics Shares Are Trading Higher After the Company Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting
Cullinan Therapeutics宣布将在2024年ASCO年会上公布其针对晚期实体瘤患者的 CLN-619 1期试验的临床数据,此后,该公司股价走高